-
Can’t Get You Out of My Head: The Huntington’s Disease Symptom That’s More Than Just Repetition
5 min read
Latest News
-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-
Huntingtin takes a trip: harmful proteins pass between brain cells
7 min read
Harmful misfolded huntingtin can travel between brain cells via messenger particles called exosomes
-
Important drug targets yielded by new genetic study of HD
8 min read
A genetic study confirms that minute differences in DNA repair genes can influence the age of HD symptom onset.
-
Thinking clearly about the earliest symptoms of HD and which brain regions control them
8 min read
HD reaches more brain structures than we thought: new research broadens our understanding of the earliest signs of HD
-
How NOT to write a news article about a clinical trial
5 min read
A confusing story about a huntingtin lowering trial is published in the Telegraph, but cool new stuff is happening!
-
Huntington's Disease Therapeutics Conference 2016 – day 3
8 min read
Stem cells and modeling Huntington's disease in our final Therapeutics Conference report
-
Huntington's Disease Therapeutics Conference 2016 – day 2
7 min read
Strategies for getting rid of mutant huntingtin & clinical trial updates: day 2 of the HD therapeutics conference
-
Huntington's Disease Therapeutics Conference 2016 – day 1
12 min read
Proteins and DNA – Jeff and Ed report from day 1 of the 2016 #huntingtonsdisease therapeutics conference
-
Harnessing the power of viruses to treat Huntington's disease
7 min read
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.
-
Through a Broader Lens: Looking at Non-Motor Symptoms in HD
8 min read
Sleep deficits precede motor problems in HD
-
Looking Past the Spin: Results from a Clinical Trial of Cysteamine
6 min read
Phase 2/3 clinical trial results prove inconclusive for Huntington's drug cysteamine.
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
